SW620 Cells

The SW-620 cell line, originating from the large intestine of a 51-year-old male with Dukes-C colorectal cancer, is a pivotal research model in colorectal cancer, especially for cancer biomarkers, chemotherapy, and the study of metastatic cancer cells.
SW-620 cells are pivotal for studying cell apoptosis and the resistance mechanisms to anoikis, a form of programmed cell death crucial for preventing metastasis. Research utilizing the SW-620 colon cancer cells has delved into proteomic analysis to understand proteome changes under different conditions, such as hypoxia. Hypoxic SW620 cells exhibit specific proteome adaptations that contribute to chemotherapy resistance.
SW620 colon cancer cells have been pivotal in evaluating natural compounds like curcumin and their impact on cancer cell viability. Studies have shown that curcumin inhibits cell viability in SW-620 cells. Moreover, the cell line aids in assessing the effects of chemotherapeutic agents and the potential for chemotherapy resistance, which is critical for advancing cancer treatment strategies.
Exhibiting high tumorigenic and metastatic capabilities, SW-620 cells form solid tumors in vivo. The SW620 xenograft model, alongside the study of specific pathways like the catenin pathway and the role of transcription factors such as cdx2 in colonic adenocarcinoma cells, enriches our understanding of colorectal cancer’s molecular underpinnings.
In summary, SW-620 human colon adenocarcinoma cells are an invaluable resource in cancer research, offering a multifaceted approach to understanding colorectal cancer’s complexities.